title: Use of blood components in cancer patients with bleeding.
abstract: The need for blood components for oncology patients is small compared with the need for patients with hematologic malignancies. The subject is important because use of these valuable components is dependent on a limited supply and availability. Agreement on when to use components is extremely important. In fact, at the time of this writing, the Transfusion Practices Committee of the American Association of Blood Banks is conducting an extensive survey on the use of platelets in oncology and hematology cancer patients (Questionnaire on Institutional Policy on Platelet Transfusion Practice for Hematology/Oncology Patients). The results will, we hope, provide a consensus on the proper times and counts that require prophylactic use of components for these patients. Because these patients use the vast majority of components (see Table 15), their proper use is imperative to maintaining an adequate platelet and frozen plasma supply. Transfusion support in cancer patients is vital for their survival. Platelets, in particular, are necessary to prevent serious bleeding. The risks from transfusion must always be considered. Fortunately, with increased monitoring of the blood supply, they have been reduced. As with any therapeutic regimen, these risks must be weighed against the benefit the patient may gain. Transfusion should always be used prudently.
authors.affiliation: Department of Medicine, University of Kansas Medical Center, Kansas City.
authors.forename: D C
authors.initials: DC
authors.lastname: Bodensteiner
authors.forename: L L
authors.initials: LL
authors.lastname: Tilzer
authors.forename: M E
authors.initials: ME
authors.lastname: Adams
authors.forename: W L
authors.initials: WL
authors.lastname: Bayer
mesh_terms: D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy; D016913:Blood Component Transfusion; D016026:Bone Marrow Transplantation; D006470:Hemorrhage / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D007615:Kansas; D007938:Leukemia / Q000150:complications; D009369:Neoplasms / Q000150:complications* / Q000628:therapy*